Prevention of plaque rupture: A new paradigm of therapy

被引:38
作者
Forrester, JS [1 ]
机构
[1] Cedars Sinai Med Ctr, Div Cardiol, Los Angeles, CA 90048 USA
关键词
D O I
10.7326/0003-4819-137-10-200211190-00012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute coronary syndromes-unstable angina, myocardial infarction, and sudden cardiac death-are caused by acute disruption of an unstable coronary atheroma. Unstable plaques have three histologic characteristics: a large lipid core, many inflammatory cells, and a thin fibrous cap. Because the unstable plaque is not necessarily obstructive, it may cause no symptoms before rupture. The cellular processes that lead to the characteristic histologic features of unstable plaque have recently been identified. This new understanding of the cell biology of plaque instability suggests new therapeutic strategies: passivation of the endothelium, reduction of low-density lipoprotein (LDL) in the vessel wall by decreasing serum LDL levels or accelerating reverse cholesterol transport, inhibition of LDL oxidation, inhibition of inflammatory cytokine expression, and inhibition of thrombus formation. Although the morbidity and mortality resulting from acute coronary disease have been reduced by more than :50% over the past 30 years, it is reasonable to anticipate further reductions of similar magnitude in the decade ahead.
引用
收藏
页码:823 / 833
页数:11
相关论文
共 103 条
[1]   Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma - A potential mechanism of lesion stabilization [J].
Aikawa, M ;
Rabkin, E ;
Okada, Y ;
Voglic, SJ ;
Clinton, SK ;
Brinckerhoff, CE ;
Sukhova, GK ;
Libby, P .
CIRCULATION, 1998, 97 (24) :2433-2444
[2]   Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection -: The azithromycin in coronary artery disease:: Elimination of myocardial infection with Chlamydia (ACADEMIC) study [J].
Anderson, JL ;
Muhlestein, JB ;
Carlquist, J ;
Allen, A ;
Trehan, S ;
Nielson, C ;
Hall, S ;
Brady, J ;
Egger, M ;
Horne, B ;
Lim, T .
CIRCULATION, 1999, 99 (12) :1540-1547
[3]   PRESENCE OF A MODIFIED LOW-DENSITY LIPOPROTEIN IN HUMANS [J].
AVOGARO, P ;
BON, GB ;
CAZZOLATO, G .
ARTERIOSCLEROSIS, 1988, 8 (01) :79-87
[4]   REGRESSION OF ATHEROSCLEROTIC LESIONS BY HIGH-DENSITY-LIPOPROTEIN PLASMA FRACTION IN THE CHOLESTEROL-FED RABBIT [J].
BADIMON, JJ ;
BADIMON, L ;
FUSTER, V .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (04) :1234-1241
[5]   DETECTION AND LOCALIZATION OF TUMOR NECROSIS FACTOR IN HUMAN ATHEROMA [J].
BARATH, P ;
FISHBEIN, MC ;
CAO, J ;
BERENSON, J ;
HELFANT, RH ;
FORRESTER, JS .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (05) :297-302
[6]  
BARATH P, 1988, J AM COLL CARDIOL, V9, P52
[7]   Inhibition of endothelial cell adhesion molecule expression by high density lipoproteins [J].
Barter, PJ .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1997, 24 (3-4) :286-287
[8]   APOPTOSIS OF HUMAN VASCULAR SMOOTH-MUSCLE CELLS DERIVED FROM NORMAL VESSELS AND CORONARY ATHEROSCLEROTIC PLAQUES [J].
BENNETT, MR ;
EVAN, GI ;
SCHWARTZ, SM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) :2266-2274
[9]   Distinct patterns of transforming growth factor-β isoform and receptor expression in human atherosclerotic lesions -: Colocalization implicates TGF-β in fibrofatty lesion development [J].
Bobik, A ;
Agrotis, A ;
Kanellakis, P ;
Dilley, R ;
Krushinsky, A ;
Smirnov, V ;
Tararak, E ;
Condron, M ;
Kostolias, G .
CIRCULATION, 1999, 99 (22) :2883-2891
[10]   HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit [J].
Bocan, TMA ;
Mueller, SB ;
Brown, EQ ;
Lee, P ;
Bocan, MJ ;
Rea, T ;
Pape, ME .
ATHEROSCLEROSIS, 1998, 139 (01) :21-30